Bloodwork Before Starting Semaglutide

Why Baseline Bloodwork Matters for Semaglutide

Semaglutide activates the GLP-1 receptor across multiple organ systems simultaneously. In the pancreas, it drives cAMP-mediated insulin secretion and beta-cell preservation. In the hypothalamus, it remodels appetite signaling through POMC activation and NPY/AgRP suppression. In the liver, it reduces hepatic fat accumulation. In the vasculature, it suppresses NF-kB-driven inflammation and shifts macrophage polarization. Because these pathways intersect glycemic control, lipid metabolism, liver function, and systemic inflammation, a single compound touches biomarkers across all four domains. Without pre-protocol baselines, there is no way to distinguish a therapeutic response from a pre-existing abnormality, and no way to quantify the magnitude of change once therapy is underway. Baseline labs establish the reference frame that makes every subsequent retest interpretable.

What to Test Before Starting

The glycemic panel is the most direct reflection of the pathways semaglutide engages. HbA1c captures three-month average glucose exposure and serves as the primary efficacy marker for GLP-1R agonist therapy. Fasting Glucose provides a point-in-time snapshot of hepatic glucose output and insulin sensitivity. Together they establish where glycemic regulation stands before semaglutide begins augmenting glucose-dependent insulin secretion through PKA and Epac2 signaling. A provider is looking for the degree of dysregulation present, which determines both the expected magnitude of response and whether concomitant diabetes medications need dose adjustment at the outset.

The metabolic and lipid panel captures the broader cardiometabolic picture. Triglycerides and a full Lipid Panel reflect hepatic VLDL output and peripheral lipid clearance, both of which shift as semaglutide reduces liver fat and drives white adipose browning through SIRT1 and AMPK modulation. ALT/AST levels quantify hepatocellular stress and are particularly relevant given semaglutide’s demonstrated effect on MASH resolution and liver fat reduction. Elevated transaminases at baseline distinguish fatty liver disease from other hepatic pathology and set the benchmark for tracking improvement.

Inflammatory status rounds out the baseline picture. hs-CRP is a systemic inflammation marker that reflects the NF-kB and macrophage reprogramming pathways semaglutide modulates. The SELECT trial linked semaglutide’s cardiovascular benefit to reductions in inflammatory burden, making hs-CRP a meaningful marker to track from day one. Baseline Body Weight is also essential, as weight trajectory is both an efficacy endpoint and a safety signal for distinguishing expected appetite-mediated loss from pathological weight change.

What to Retest and When

At 4 weeks, retest Fasting Glucose to assess early glycemic response. Fasting glucose decreases relatively quickly as GLP-1R-mediated insulin secretion and glucagon suppression take effect. Body Weight should also be recorded at this interval to confirm the expected downward trajectory from hypothalamic appetite suppression.

At 12 weeks, retest the full panel. HbA1c decreases measurably by this point, reflecting the cumulative effect of improved glucose-dependent insulin dynamics over the preceding three months. hs-CRP decreases as systemic inflammation attenuates through macrophage reprogramming. ALT/AST normalizes in patients where hepatic fat reduction is occurring. The Lipid Panel and Triglycerides normalize as hepatic lipid metabolism rebalances. These 12-week results provide the first complete picture of multi-system response and inform whether the current dose is producing adequate effect across metabolic, hepatic, and inflammatory domains.

Your provider may adjust timing based on your baseline values and how you’re responding.

Red Flags — When to Pause and Retest

A significant rise in lipase or amylase warrants immediate protocol review, given the established risk of acute pancreatitis including fatal hemorrhagic and necrotizing forms. Rapidly falling glucose or symptoms of hypoglycemia are critical signals, particularly in patients on concurrent insulin or sulfonylureas where additive hypoglycemic effects are documented. Worsening liver enzymes rather than the expected normalization pattern suggest hepatic pathology unrelated to fatty liver and require further workup. Thyroid function changes, especially calcitonin elevations, require prompt evaluation given the boxed warning for thyroid C-cell tumors observed in preclinical models.

How This Fits Your Broader Protocol

The frontmatter for semaglutide does not currently list common peptide stacks, but any compounds added alongside it will shift which biomarkers deserve closer attention and more frequent retesting. Review the full interaction profile at semaglutide contraindications before layering additional therapies. For real-time compound interaction screening, use the interaction checker.